Mercado de Tratamento da Dengue Ásia-Pacífico – Tendências da Indústria e Previsão para 2028

Pedido de resumo Pedido de TOC Fale com Analista Fale com o analista  Comprar agora Comprar agora Consulte antes Comprar Consulte antes Relatório de amostra grátis Relatório de amostra grátis

Mercado de Tratamento da Dengue Ásia-Pacífico – Tendências da Indústria e Previsão para 2028

  • Pharmaceutical
  • Publish Reports
  • Feb 2021
  • Asia-Pacific
  • 350 Páginas
  • Número de tabelas: 212
  • Número de figuras: 52

>Mercado de tratamento da dengue Ásia-Pacífico, por estirpes (DENV-1, DENV-2, DENV-3, DENV-4, outras), transmissão (transmissão mosquito-humano e transmissão mãe-filho), tipo (medicamento, Cuidados de suporte, vacinação e outros), gravidade (descomplicada e grave), via de administração (oral e parentérica), modo de compra (prescrição e balcão (OTC)), utilizador final (hospitais, clínicas especializadas, assistência médica domiciliária e Outros), Canal de Distribuição (Farmácias Hospitalares, Farmácias de Retalho, Farmácias Online e Outras), País (Japão, China, Austrália, Coreia do Sul, Índia, Singapura, Tailândia, Indonésia, Malásia, Filipinas, Vietname, Resto da Ásia-Pacífico) Indústria Tendências e previsões para 2028

Mercado Ásia-Pacífico de Tratamento da DengueAnálise e insights de mercado: Mercado de tratamento da dengue da Ásia-Pacífico

Espera-se que o mercado de tratamento da dengue ganhe crescimento de mercado no período de previsão de 2021 a 2028. A Data Bridge Market Research analisa que o mercado está a crescer com um CAGR de 26,3% no período de previsão de 2021 a 2028 e deverá atingir os 1.941,62 dólares até 2028. As iniciativas estratégicas dos participantes do mercado e o advento de programas de vacinação em massa para o tratamento da dengue serão provavelmente os principais impulsionadores do mercado de tratamento da dengue.

A dengue é uma doença viral transmitida por mosquitos que se tem espalhado rapidamente em todas as regiões da OMS (Organização Mundial de Saúde) nos últimos anos. O vírus da dengue é transmitido principalmente por mosquitos fêmeas do género Aedes aegypti e, em menor escala, pelo Ae. albopictus. As doenças transmitidas por estes mosquitos vetores são a chikungunya, a febre amarela e o vírus Zika. A dengue é prevalente nos trópicos, induzida pela precipitação, temperatura, humidade relativa e urbanização rápida e não planeada, com variabilidade de risco local.

Apesar das medidas controladas, o aumento global da incidência de dengue, juntamente com o aumento da frequência de surtos localizados e o potencial de floração das espécies de Aedes, levam ao aumento do consumo da opção de tratamento para o tratamento da dengue e espera-se que atue como um impulsionador para o mercado de tratamento da dengue. O custo do tratamento da dengue é mais elevado conforme listado na declaração acima e com mais complicações relacionadas com a dengue, como falência de múltiplos órgãos e outras, pode aumentar o custo total para os resultados da terapia na pessoa infetada, evitando terapias adequadas para o tratamento da dengue, pode, portanto, atuar como um contenção para o mercado de tratamento da dengue. A dengue pode ser tradicionalmente diagnosticada por testes serológicos, mas agora, com a atualização tecnológica, existem diferentes formas contínuas e desenvolvidas para a deteção do vírus, o que criará uma oportunidade para o mercado de tratamento da dengue. A dengue é uma doença transmitida por vetores com medicamentos inespecíficos, como antipiréticos e alguns antibióticos, mas espera-se que as medidas preventivas e as iniciativas tomadas pelas diferentes agências governamentais em todo o mundo funcionem como um desafio para o mercado de tratamento da dengue.     

O relatório do mercado de tratamento da dengue fornece detalhes da quota de mercado, novos desenvolvimentos e impacto dos participantes do mercado doméstico e localizado, analisa as oportunidades em termos de bolsas de receitas emergentes, alterações nas regulamentações do mercado, aprovações de produtos, decisões estratégicas, lançamentos de produtos, expansões geográficas e inovações tecnológicas do mercado. Para compreender a análise e o cenário do mercado de tratamento da dengue, contacte a Data Bridge Market Research para obter um resumo do analista, a nossa equipa irá ajudá-lo a criar uma solução de impacto na receita para atingir o objetivo desejado.

Mercado Ásia-Pacífico de Tratamento da DengueÂmbito do mercado de tratamento da dengue e dimensão do mercado

O mercado de tratamento da dengue está segmentado com base nas estirpes, transmissão, tipo, gravidade, via de administração, modo de compra, utilizador final e canal de distribuição. O crescimento entre segmentos ajuda-o a analisar os nichos de crescimento e as estratégias para abordar o mercado e determinar as suas principais áreas de aplicação e a diferença nos seus mercados-alvo.

  • Com base nas estirpes, o mercado de tratamento da dengue está segmentado em DENV-1, DENV-2, DENV-3, DENV-4, outros. Em 2021, o segmento DENV-2 está a dominar o mercado, uma vez que esta estirpe tem uma elevada prevalência a nível global, o que resulta em maiores casos de infeção por dengue.
  • Com base na transmissão, o mercado de tratamento da dengue está segmentado em transmissão mosquito-humano e transmissão mãe-filho. Em 2021, o segmento da transmissão mosquito-humano está a dominar o mercado, uma vez que os mosquitos são o principal vetor para a transmissão da dengue às diferentes estirpes do vírus.
  • Com base no tipo, o mercado de tratamento da dengue está segmentado em medicamentos, cuidados de suporte, vacinação e outros. Em 2021, o segmento dos medicamentos está a dominar o mercado, uma vez que vários medicamentos utilizados no tratamento da dengue estão a ser utilizados há muito tempo no tratamento da dengue.
  • Com base na gravidade, o mercado de tratamento da dengue está segmentado em descomplicado e grave. Em 2021, o segmento não complicado está a dominar o mercado, uma vez que a taxa de conversão da dengue não complicada em dengue grave é inferior a 5%, que é a razão mais importante pela qual o segmento não complicado está a dominar o mercado de tratamento da dengue.
  • Com base na via de administração, o mercado de tratamento da dengue está segmentado em oral e parentérica. Em 2021, o segmento oral está a dominar o mercado, uma vez que a maioria dos medicamentos tomados para tratar os sintomas da dengue são tomados por via oral para o controlo da dor e da febre.
  • Com base na forma de compra, o mercado de tratamento da dengue está segmentado em prescrição e venda livre (OTC). Em 2021, o segmento de prescrição domina o mercado, uma vez que os medicamentos e os cuidados de suporte são prescritos pelos médicos após a confirmação de que o doente está infetado pelo vírus da dengue e as opções de tratamento consistem em antibióticos e outros medicamentos que geralmente não estão disponíveis como medicamentos apenas sujeitos a receita médica.
  • On the basis of end user, the dengue treatment market is segmented into hospitals, specialty clinics, home healthcare and others. In 2021, home healthcare segment is dominating in the market as the symptoms of dengue can be managed at home using medications such as pain relief and fever management drugs after the diagnosis.
  • On the basis of distribution channel, the dengue treatment market is segmented into hospital pharmacies, retail pharmacies, online pharmacies and others. In 2021, retail pharmacies segment is dominating in the market as after proper diagnosis of dengue, most of the prescriptions by patients are filled in retail pharmacies during the total duration of the treatment cycle of the infection.

Asia-Pacific Dengue Treatment Market Country Level Analysis

Asia-Pacific dengue treatment market is analysed and market size information is provided by the country, strains, transmission, type, severity, route of administration, mode of purchase, end user and distribution channel as referenced above.

The countries covered in the Asia-Pacific dengue treatment market report are the Japan, China, Australia, South Korea, India, Singapore, Thailand, Indonesia, Malaysia, Philippines, Vietnam and rest of Asia-Pacific.

Asia-Pacific is expected to grow with the highest CAGR in the forecast period as in the Asia-Pacific’s countries, the demand for dengue treatment products is increasing very rapidly with the urbanization and laboratory automation. China is expected to dominate in the Asia-Pacific dengue treatment market as China is one of the leading countries to inculcate dengue treatment market.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.  

Necessity of Dengue Treatment in Urban Areas and the Strategic Initiatives by Market Players are is creating new opportunities for Players in the Dengue Treatment Market 

The dengue treatment market also provides you with detailed market analysis for every country growth in particular industry with dengue treatment sales, impact of advancement in the dengue treatment and changes in regulatory scenarios with their support for the dengue treatment market. The data is available for historic period 2011 to 2019.

Competitive Landscape and Dengue Treatment Market Share Analysis

O panorama competitivo do mercado de tratamento da dengue fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, localizações e instalações de produção, pontos fortes e fracos da empresa, lançamento de produtos, pipelines de testes de produtos, aprovações de produtos, patentes, largura e amplitude do produto, domínio de aplicação, curva de segurança da tecnologia. Os dados acima fornecidos estão apenas relacionados com o foco da empresa relacionado com o mercado de tratamento da dengue.

As principais empresas que estão a negociar no relatório do mercado de tratamento da dengue da Ásia-Pacífico são a Takeda Pharmaceutical Company Limited, Sanofi, GlaxoSmithKline plc, Aurobindo Pharma, Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Pfizer Inc., Dr. Baxter, Viatris Inc. entre outros players nacionais. Os analistas DBMR compreendem os pontos fortes competitivos e fornecem análises competitivas para cada concorrente em separado.

As iniciativas estratégicas dos intervenientes no mercado com investimento de capital para a investigação da dengue estão a preencher a lacuna entre a dengue e o seu tratamento no mercado de tratamento da dengue.

Por exemplo,

  • Em novembro de 2020, a Viatris Inc. foi lançada como uma combinação de dois negócios Mylan NV e Pfizer Upjohn. Esta combinação dos dois terá como foco a melhoria da saúde do paciente. A Viatris Inc. tem experiência em produção científica e distribuição com capacidades médicas, regulamentares e comerciais globais comprovadas para fornecer medicamentos de alta qualidade a doentes em mais de 165 países e territórios. Este lançamento de uma nova empresa aumentará a receita da empresa num futuro próximo.

A colaboração, as joint ventures e outras estratégias dos players do mercado estão a potenciar o mercado da empresa no mercado de tratamento da dengue, o que também oferece o benefício para a organização melhorar a sua oferta para o mercado de tratamento da dengue.   

 

 


SKU-

Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo

  • Painel interativo de análise de dados
  • Painel de análise da empresa para oportunidades de elevado potencial de crescimento
  • Acesso de analista de pesquisa para personalização e customização. consultas
  • Análise da concorrência com painel interativo
  • Últimas notícias, atualizações e atualizações Análise de tendências
  • Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Pedido de demonstração

Índice

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF ASIA-PACIFIC DENGUE TREATMENT MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 STRAINS LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHT

5 PIPELINE ANALYSIS

6 ASIA-PACIFIC DENGUE TREATMENT MARKET: REGULATIONS

6.1 U.S. REGULATORY SCENARIO FOR DENGUE TREATMENT

6.2 EUROPE REGULATORY SCENARIO FOR DENGUE TREATMENT

6.3 DEVELOPING COUNTRIES REGULATORY FRAMEWORK

6.4 LEGISLATION FOR CONTROL OF DENGUE IN SINGAPORE

6.5 DVCRN DEVELOPING VACCINE REGULATORS NETWORK

7 CLINICAL STUDIES FOR DENGUE TREATMENT PRODUCTS.

7.1 SYNTHETIC DRUGS

7.2 BIOMARKER

7.3 DIRECT ACTING ANTIVIRAL DRUGS

8 EPIDEMIOLOGY

9 MARKET OVERVIEW

9.1 DRIVERS

9.1.1 INCREASING INCIDENCE IN DENGUE CASES

9.1.2 ADVENT OF VACCINATION PROGRAMS

9.1.3 INCREASE IN RESEARCH AND DEVELOPMENT FUNDING

9.1.4 ROLE OF IGM AND IGG ANTIBODIES IN DENGUE

9.1.5 GROWTH OF MEDICAL INSURANCE IN EMERGING COUNTRIES

9.2 RESTRAINTS

9.2.1 HIGH COST OF TREATMENT

9.2.2 DEARTH AWARENESS ABOUT THE SYMPTOMS OF DENGUE

9.2.3 LACK OR INSUFFICIENT HEALTHCARE INFRASTRUCTURE

9.3 OPPORTUNITIES

9.3.1 NEED FOR DENGUE TREATMENT IN URBAN AREAS

9.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS

9.3.3 TECHNOLOGICAL ADVANCEMENT IN DENGUE VIRUS DETECTION

9.3.4 INCREASE IN ASIA-PACIFIC TRAVEL AND RELATION WITH DENGUE

9.4 CHALLENGES

9.4.1 PRESENCE OF PREVENTIVE MEASURES FOR DENGUE AND IT’S SPREAD

9.4.2 CHALLENGES IN DETECTION ASSAY FOR DENGUE

9.4.3 ALTERNATIVES FOR DENGUE TREATMENT

10 IMPACT OF COVID-19 ON ASIA-PACIFIC DENGUE TREATMENT MARKET

10.1 IMPACT ON PRICE

10.2 IMPACT ON DEMAND

10.3 IMPACT ON SUPPLY CHAIN

10.4 STRATEGIC DECISION BY MANUFACTURERS

10.5 KEY INITIATIVES BY MARKET PLAYERS DURING COVID-19

10.6 CONCLUSION

11 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY STRAINS

11.1 OVERVIEW

11.2 DENV-3

11.3 DENV-2

11.4 DENV-1

11.5 DENV-4

11.6 OTHERS

12 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY TRANSMISSION

12.1 OVERVIEW

12.2 MOSQUITO-TO-HUMAN TRANSMISSION

12.3 MOTHER-TO-CHILD- TRANSMISSION

12.4 OTHERS

13 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY TYPE

13.1 OVERVIEW

13.2 MEDICATION

13.2.1 ACETAMINOPHEN

13.2.2 ANTIBIOTICS

13.2.2.1 Ciprofloxacin

13.2.2.2 Chloramphenicol

13.2.2.3 Ceftriaxone

13.2.2.4 Ofloxacin

13.2.2.5 Others

13.2.3 IMMUNOGLOBULINS

13.2.4 CORTICOSTEROIDS

13.2.5 ANTI-VIRALS

13.2.6 OTHERS

13.3 SUPPORTIVE CARE

13.4 VACCINATION

13.4.1 DENGVAXIA (CYD-TDV)

13.4.2 DENVAX (TAK-003)

13.4.3 TETRAVAX-DV

13.4.4 TDEN PIV

13.5 OTHERS

14 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY SEVERITY

14.1 OVERVIEW

14.2 UNCOMPLICATED

14.3 SEVERE

15 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

15.1 OVERVIEW

15.2 ORAL

15.2.1 TABLET

15.2.2 CAPSULES

15.2.3 OTHERS

15.3 PARENTERAL

15.3.1 INTRAVENOUS

15.3.2 SUBCUTANEOUS

15.3.3 OTHERS

16 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY MODE OF PURCHASE

16.1 OVERVIEW

16.2 PRESCRIPTION

16.3 OVER THE COUNTER (OTC)

17 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY END USER

17.1 OVERVIEW

17.2 HOME HEALTHCARE

17.3 HOSPITALS

17.4 SPECIALTY CLINICS

17.5 OTHERS

18 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL

18.1 OVERVIEW

18.2 RETAIL PHARMACIES

18.3 HOSPITAL PHARMACY

18.4 ONLINE PHARMACY

18.5 OTHERS

19 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY GEOGRAPHY

19.1 ASIA-PACIFIC

19.1.1 MALAYSIA

19.1.2 PHILIPPINES

19.1.3 VIETNAM

19.1.4 INDONESIA

19.1.5 INDIA

19.1.6 THAILAND

19.1.7 SINGAPORE

19.1.8 AUSTRALIA

19.1.9 CHINA

19.1.10 JAPAN

19.1.11 SOUTH KOREA

19.1.12 REST OF ASIA-PACIFIC

20 ASIA-PACIFIC DENGUE TREATMENT MARKET, COMPANY LANDSCAPE

20.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

21 SWOT ANALYSIS

22 COMPANY PROFILE

22.1 VIATRIS INC.

22.1.1 COMPANY SNAPSHOT

22.1.2 COMPANY SHARE ANALYSIS

22.1.3 PRODUCT PORTFOLIO

22.1.4 RECENT DEVELOPMENT

22.2 PFIZER INC.

22.2.1 COMPANY SNAPSHOT

22.2.2 REVENUE ANALYSIS

22.2.3 COMPANY SHARE ANALYSIS

22.2.4 PRODUCT PORTFOLIO

22.2.5 RECENT DEVELOPMENTS

22.3 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)

22.3.1 COMPANY SNAPSHOT

22.3.2 REVENUE ANALYSIS

22.3.3 COMPANY SHARE ANALYSIS

22.3.4 PRODUCT PORTFOLIO

22.3.5 RECENT DEVELOPMENT

22.4 PERRIGO COMPANY PLC

22.4.1 COMPANY SNAPSHOT

22.4.2 REVENUE ANALYSIS

22.4.3 COMPANY SHARE ANALYSIS

22.4.4 PRODUCT PORTFOLIO

22.4.5 RECENT DEVELOPMENTS

22.5 GLAXOSMITHKLINE PLC

22.5.1 COMPANY SNAPSHOT

22.5.2 REVENUE ANALYSIS

22.5.3 COMPANY SHARE ANALYSIS

22.5.4 PRODUCT PORTFOLIO

22.5.5 RECENT DEVELOPMENT

22.6 DR. REDDY’S LABORATORIES LTD.

22.6.1 COMPANY SNAPSHOT

22.6.2 REVENUE ANALYSIS

22.6.3 PRODUCT PORTFOLIO

22.6.4 RECENT DEVELOPMENT

22.7 FRESENIUS KABI USA (A SUBSIDIARY OF FRESENIUS SE & CO. KGAA)

22.7.1 COMPANY SNAPSHOT

22.7.2 REVENUE ANALYSIS

22.7.3 PRODUCT PORTFOLIO

22.7.4 RECENT DEVELOPMENTS

22.8 SUN PHARMACEUTICAL INDUSTRIES LTD.

22.8.1 COMPANY SNAPSHOT

22.8.2 REVENUE ANALYSIS

22.8.3 PRODUCT PORTFOLIO

22.8.4 RECENT DEVELOPMENTS

22.9 ABIVAX

22.9.1 COMPANY SNAPSHOT

22.9.2 PRODUCT PORTFOLIO

22.9.3 RECENT DEVELOPMENTS

22.1 AUROBINDO PHARMA

22.10.1 COMPANY SNAPSHOT

22.10.2 REVENUE ANALYSIS

22.10.3 PRODUCT PORTFOLIO

22.10.4 RECENT DEVELOPMENTS

22.11 BAXTER

22.11.1 COMPANY SNAPSHOT

22.11.2 REVENUE ANALYSIS

22.11.3 PRODUCT PORTFOLIO

22.11.4 RECENT DEVELOPMENT

22.12 EMERGEX VACCINES

22.12.1 COMPANY SNAPSHOT

22.12.2 PRODUCT PORTFOLIO

22.12.3 RECENT DEVELOPMENTS

22.13 HIKMA PHARMACEUTICALS PLC

22.13.1 COMPANY SNAPSHOT

22.13.2 REVENUE ANALYSIS

22.13.3 PRODUCT PORTFOLIO

22.13.4 RECENT DEVELOPMENT

22.14 SANOFI

22.14.1 COMPANY SNAPSHOT

22.14.2 REVENUE ANALYSIS

22.14.3 PRODUCT PORTFOLIO

22.14.4 RECENT DEVELOPMENTS

22.15 TAKEDA PHARMACEUTICAL COMPANY LIMITED

22.15.1 COMPANY SNAPSHOT

22.15.2 REVENUE ANALYSIS

22.15.3 PRODUCT PORTFOLIO

22.15.4 RECENT DEVELOPMENTS

23 QUESTIONNAIRE

24 RELATED REPORTS

Lista de Tabela

LIST OF TABLES 

TABLE 1 ASIA-PACIFIC DENGUE TREATMENT MARKET, PIPELINE ANALYSIS

TABLE 2 THREE PHASES FOR HEALTH PROTECTION OUTLINED BY THE EUROPEAN WORLD HEALTH ORGANIZATION

TABLE 3 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY STRAINS 2019-2028 (USD MILLION)

TABLE 4 ASIA-PACIFIC DENV-3 IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 5 ASIA-PACIFIC DENV-2 IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 6 ASIA-PACIFIC DENV-1 IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 7 ASIA-PACIFIC DENV-4 IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 8 ASIA-PACIFIC OTHERS IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 9 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)

TABLE 10 ASIA-PACIFIC MOSQUITO-TO-HUMAN TRANSMISSION IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 11 ASIA-PACIFIC MOTHER-TO-CHILD TRANSMISSION IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 12 ASIA-PACIFIC OTHERS IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 13 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 14 ASIA-PACIFIC MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 15 ASIA-PACIFIC MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION), BY REGION

TABLE 16 ASIA-PACIFIC ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 17 ASIA-PACIFIC OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 18 ASIA-PACIFIC SUPPORTIVE CARE IN DENGUE TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION

TABLE 19 ASIA-PACIFIC VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 20 ASIA-PACIFIC VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION), BY REGION

TABLE 21 ASIA-PACIFIC OTHERS IN DENGUE TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION), BY REGION

TABLE 22 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY SEVERITY 2019-2028 (USD MILLION)

TABLE 23 ASIA-PACIFIC UNCOMPLICATED IN DENGUE TREATMENT MARKET, BY REGION 2019-2028 (USD MILLION)

TABLE 24 ASIA-PACIFIC SEVERE IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 25 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 26 ASIA-PACIFIC ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION), BY REGION

TABLE 27 ASIA-PACIFIC ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 28 ASIA-PACIFIC PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION), BY REGION

TABLE 29 ASIA-PACIFIC PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 30 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 31 ASIA-PACIFIC PRESCRIPTION IN DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION), BY REGION

TABLE 32 ASIA-PACIFIC OVER THE COUNTER (OTC) IN DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION), BY REGION

TABLE 33 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 34 ASIA-PACIFIC HOME HEALTHCARE IN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION), BY REGION

TABLE 35 ASIA-PACIFIC HOSPITALS IN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION), BY REGION

TABLE 36 ASIA-PACIFIC SPECIALTY CLINICS IN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION), BY REGION

TABLE 37 ASIA-PACIFIC OTHERS IN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION), BY REGION

TABLE 38 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 39 ASIA-PACIFIC DIRECT TENDER IN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION), BY REGION

TABLE 40 ASIA-PACIFIC HOSPITAL PHARMACY IN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION), BY REGION

TABLE 41 ASIA-PACIFIC ONLINE PHARMACY IN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION), BY REGION

TABLE 42 ASIA-PACIFIC HOSPITALS IN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION), BY REGION

TABLE 43 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 44 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)

TABLE 45 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)

TABLE 46 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 47 ASIA-PACIFIC MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 48 ASIA-PACIFIC ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 49 ASIA-PACIFIC OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 50 ASIA-PACIFIC VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 51 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 52 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 53 ASIA-PACIFIC ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 54 ASIA-PACIFIC PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 55 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 56 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 57 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 58 MALAYSIA DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)

TABLE 59 MALAYSIA DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)

TABLE 60 MALAYSIA DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 61 MALAYSIA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 62 MALAYSIA ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 63 MALAYSIA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 64 MALAYSIA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 65 MALAYSIA DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 66 MALAYSIA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 67 MALAYSIA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 68 MALAYSIA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 69 MALAYSIA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 70 MALAYSIA DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 71 MALAYSIA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 72 PHILIPPINES DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)

TABLE 73 PHILIPPINES DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)

TABLE 74 PHILIPPINES DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 75 PHILIPPINES MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 76 PHILIPPINES ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 77 PHILIPPINES OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 78 PHILIPPINES VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 79 PHILIPPINES DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 80 PHILIPPINES DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 81 PHILIPPINES ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 82 PHILIPPINES PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 83 PHILIPPINES DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 84 PHILIPPINES DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 85 PHILIPPINES DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 86 VIETNAM DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)

TABLE 87 VIETNAM DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)

TABLE 88 VIETNAM DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 89 VIETNAM MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 90 VIETNAM ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 91 VIETNAM OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 92 VIETNAM VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 93 VIETNAM DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 94 VIETNAM DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 95 VIETNAM ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 96 VIETNAM PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 97 VIETNAM DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 98 VIETNAM DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 99 VIETNAM DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 100 INDONESIA DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)

TABLE 101 INDONESIA DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)

TABLE 102 INDONESIA DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 103 INDONESIA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 104 INDONESIA ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 105 INDONESIA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 106 INDONESIA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 107 INDONESIA DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 108 INDONESIA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 109 INDONESIA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 110 INDONESIA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 111 INDONESIA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 112 INDONESIA DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 113 INDONESIA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 114 INDIA DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)

TABLE 115 INDIA DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)

TABLE 116 INDIA DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 117 INDIA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 118 INDIA ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 119 INDIA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 120 INDIA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 121 INDIA DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 122 INDIA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 123 INDIA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 124 INDIA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 125 INDIA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 126 INDIA DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 127 INDIA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 128 THAILAND DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)

TABLE 129 THAILAND DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)

TABLE 130 THAILAND DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 131 THAILAND MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 132 THAILAND ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 133 THAILAND OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 134 THAILAND VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 135 THAILAND DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 136 THAILAND DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 137 THAILAND ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 138 THAILAND PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 139 THAILAND DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 140 THAILAND DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 141 THAILAND DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 142 SINGAPORE DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)

TABLE 143 SINGAPORE DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)

TABLE 144 SINGAPORE DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 145 SINGAPORE MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 146 SINGAPORE ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 147 SINGAPORE OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 148 SINGAPORE VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 149 SINGAPORE DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 150 SINGAPORE DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 151 SINGAPORE ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 152 SINGAPORE PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 153 SINGAPORE DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 154 SINGAPORE DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 155 SINGAPORE DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 156 AUSTRALIA E DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)

TABLE 157 AUSTRALIA DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)

TABLE 158 AUSTRALIA DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 159 AUSTRALIA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 160 AUSTRALIA ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 161 AUSTRALIA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 162 AUSTRALIA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 163 AUSTRALIA DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 164 AUSTRALIA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 165 AUSTRALIA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 166 AUSTRALIA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 167 AUSTRALIA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 168 AUSTRALIA DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 169 AUSTRALIA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 170 CHINA DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)

TABLE 171 CHINA DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)

TABLE 172 CHINA DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 173 CHINA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 174 CHINA ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 175 CHINA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 176 CHINA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 177 CHINA DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 178 CHINA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 179 CHINA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 180 CHINA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 181 CHINA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 182 CHINA DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 183 CHINA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 184 JAPAN DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)

TABLE 185 JAPAN DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)

TABLE 186 JAPAN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 187 JAPAN MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 188 JAPAN ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 189 JAPAN OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 190 JAPAN VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 191 JAPAN DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 192 JAPAN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 193 JAPAN ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 194 JAPAN PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 195 JAPAN DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 196 JAPAN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 197 JAPAN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 198 SOUTH KOREA DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)

TABLE 199 SOUTH KOREA DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)

TABLE 200 SOUTH KOREA DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 201 SOUTH KOREA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 202 SOUTH KOREA ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 203 SOUTH KOREA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 204 SOUTH KOREA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 205 SOUTH KOREA DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 206 SOUTH KOREA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 207 SOUTH KOREA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 208 SOUTH KOREA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 209 SOUTH KOREA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 210 SOUTH KOREA DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 211 SOUTH KOREA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 212 REST OF ASIA-PACIFIC DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)

 

Lista de Figura

LIST OF FIGURES 

FIGURE 1 ASIA-PACIFIC DENGUE TREATMENT MARKET: SEGMENTATION

FIGURE 2 ASIA-PACIFIC DENGUE TREATMENT MARKET : DATA TRIANGULATION

FIGURE 3 ASIA-PACIFIC DENGUE TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 ASIA-PACIFIC DENGUE TREATMENT MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA-PACIFIC DENGUE TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA-PACIFIC DENGUE TREATMENT MARKET: MULTIVARIATE MODELLING

FIGURE 7 ASIA-PACIFIC DENGUE TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 ASIA-PACIFIC DENGUE TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 9 ASIA-PACIFIC DENGUE TREATMENT MARKET: MARKET END USER GRID

FIGURE 10 ASIA-PACIFIC DENGUE TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 ASIA-PACIFIC DENGUE TREATMENT MARKET: SEGMENTATION

FIGURE 12 INCREASING INCIDENCE OF DENGUE CASES AND ADVENT OF VACCINATION PROGRAMS ARE DRIVING THE ASIA-PACIFIC DENGUE TREATMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 13 FUNGAL DENGUE TREATMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC DENGUE TREATMENT MARKET IN 2021 & 2028

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGE OF ASIA-PACIFIC DENGUE TREATMENT MARKET

FIGURE 15 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY STRAINS, 2020

FIGURE 16 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY STRAINS, 2020-2028 (USD MILLION)

FIGURE 17 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY STRAINS, CAGR (2021-2028)

FIGURE 18 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY STRAINS, LIFELINE CURVE

FIGURE 19 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY TRANSMISSION, 2020

FIGURE 20 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY TRANSMISSION 2020-2028 (USD MILLION)

FIGURE 21 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY TRANSMISSION, CAGR (2021-2028)

FIGURE 22 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY TRANSMISSION, LIFELINE CURVE

FIGURE 23 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY TYPE, 2020

FIGURE 24 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY TYPE, 2020-2028 (USD MILLION)

FIGURE 25 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY TYPE, CAGR (2020-2028)

FIGURE 26 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY TYPE, LIFELINE CURVE

FIGURE 27 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY SEVERITY, 2020

FIGURE 28 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY SEVERITY , 2020-2028 (USD MILLION)

FIGURE 29 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY SEVERITY, CAGR (2021-2028).

FIGURE 30 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY SEVERITY, LIFELINE CURVE

FIGURE 31 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020

FIGURE 32 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2028 (USD MILLION)

FIGURE 33 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2028)

FIGURE 34 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 35 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, 2020

FIGURE 36 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, 2020-2028 (USD MILLION)

FIGURE 37 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, CAGR (2020-2028)

FIGURE 38 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, LIFELINE CURVE

FIGURE 39 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY END USER, 2020

FIGURE 40 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY END USER, 2020-2028 (USD MILLION)

FIGURE 41 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY END USER, CAGR (2020-2028)

FIGURE 42 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 43 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 44 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)

FIGURE 45 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2028)

FIGURE 46 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 47 ASIA-PACIFIC DENGUE TREATMENT MARKET: SNAPSHOT (2020)

FIGURE 48 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY COUNTRY (2020)

FIGURE 49 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY COUNTRY (2021 & 2028)

FIGURE 50 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY COUNTRY (2021 & 2028)

FIGURE 51 ASIA-PACIFIC DENGUE TREATMENT MARKET: BY STRAINS (2021-2028)

FIGURE 52 ASIA-PACIFIC DENGUE TREATMENT MARKET: COMPANY SHARE 2020 (%)

 

View Detailed Information Right Arrow

Metodologia de Investigação

A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados ​​e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.

A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis ​​de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.

Personalização disponível

A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.

Perguntas frequentes

The Asia-Pacific Dengue Treatment Market is projected to grow at a CAGR of 26.3% during the forecast period by 2028.
The future market value of the Asia-Pacific Dengue Treatment Market is expected to reach USD 1,941.62 million by 2028.
The major players in the Asia-Pacific Dengue Treatment Market are akeda Pharmaceutical Company Limited, Sanofi, GlaxoSmithKline plc, Aurobindo Pharma, Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Pfizer Inc., etc.
The countries covered in the Asia-Pacific Dengue Treatment Market are Japan, China, Australia, South Korea, India, Singapore, Thailand, Indonesia, Malaysia, Philippines, Vietnam and rest of Asia-Pacific